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Abstract – A 20 kg German shepherd dog was presented to a French veterinary teaching hospital for seizures and
hyperthermia. The dog had returned 1 month previously from a six-month stay in Senegal and sub-Saharan Africa.
Biochemistry and haematology showed severe hypoglycaemia (0.12 g/L), anaemia and thrombocytopenia. Despite
administration of large amounts of glucose (30 mL of 30% glucose IV and 10 mL of 70% sucrose by gavage tube
hourly), 26 consecutive blood glucose measurements were below 0.25 g/L (except one). Routine cytological exami-
nation of blood smears revealed numerous free extracytoplasmic protozoa consistent with Trypanosoma congolense.
PCR confirmed a Trypanosoma congolense forest-type infection. Treatment consisted of six injections of pentamidine
at 48-hour intervals. Trypanosomes had disappeared from the blood smears four days following the first injection.
Clinical improvement was correlated with the normalization of laboratory values. The infection relapsed twice and
the dog was treated again; clinical signs and parasites disappeared and the dog was considered cured; however, 6 years
after this incident, serological examination by ELISA T. congolense was positive. The status of this dog (infected or
non-infected) remains unclear. Hypoglycaemia was the most notable clinical feature in this case. It was spectacular in
its severity and in its refractory nature; glucose administration seemed only to feed the trypanosomes, indicating that
treatment of hypoglycaemia may in fact have been detrimental.
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Résumé – Hypoglycémie réfractaire chez un chien infecté par Trypanosoma congolense. Un chien Berger
allemand de 20 kg a été présenté à un hôpital universitaire vétérinaire français pour convulsions et hyperthermie. Le
chien était revenu un mois auparavant d’un séjour de 6 mois au Sénégal et en Afrique sub-saharienne. La biochimie
et l’hématologie ont montré une hypoglycémie sévère (0.12 g/L), une anémie et une thrombocytopénie. Malgré
l’administration de grandes quantités de glucose (30 mL de glucose 30 % par voie IV et 10 mL de sirop de sucre à
70 % par une sonde naso-oesophagienne, chaque heure) 26 mesures consécutives de la glycémie (sauf une) étaient
inférieures à 0,25 g/L. Un examen cytologique de routine de frottis sanguins a révélé de nombreux protozoaires
extracytoplasmiques libres compatibles avec Trypanosoma congolense. La PCR a confirmé une infection par
Trypanosoma congolense de type forêt. Le traitement a consisté en 6 injections de pentamidine à 48 heures
d’intervalles. Les trypanosomes ont disparu des frottis sanguins 4 jours après la première injection. L’amélioration
clinique a été corrélée à la normalisation des valeurs de laboratoire. L’infection a rechuté 2 fois et l’animal a reçu de
nouveaux traitements ; les signes cliniques et les parasites ont disparu et le chien a été considéré comme guéri ;
toutefois, six ans après cet incident, le test ELISA pour T. congolense était positif. Le statut de ce chien (infecté ou
non infecté) demeure incertain. L’hypoglycémie était la caractéristique clinique la plus notable de ce cas. Elle était
spectaculaire dans sa sévérité et dans son caractère réfractaire ; l’administration de glucose ne semblait que nourrir
les trypanosomes laissant à penser que le traitement de l’hypoglycémie avait pu en fait être néfaste.
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1. Case presentation
1.1. Signalment – history
A 20 kg, 2-year-old intact female mixed-breed German
shepherd dog was referred to the Emergency unit of the Nantes
Veterinary Teaching Hospital (France) for several seizures and
persistent hyperthermia. The dog had returned 1 month previ-
ously from a six-month stay in Senegal and sub-Saharan
Africa. She had been properly vaccinated and dewormed.
The rabies antibody titre was 7.92 IU/mL, above the value
required for re-entry to Europe. The owners reported lethargy,
reduced appetite, weight loss and fever peaks > 40 C for
6 weeks. The dog had no history of epilepsy.
1.2. Physical examination
At presentation, the dog was cachectic, sleepy but respon-
sive, sternally or laterally recumbent (Fig. 1), with hyperther-
mia (39.9 C). Physical examination revealed pale mucous
membranes, capillary refill less than 2 s, normal hydration,
tachypnoea (60 breaths/min) and tachycardia (heart rate
140 bpm). There were no petechiae. The skin showed sequelae
of myiasis (most probably due to Cordylobia anthropophaga),
but no ulcers. A tick (female Rhipicephalus sanguineus) was
identified on the coat. Superficial lymph nodes were enlarged,
especially the popliteal lymph nodes. There was no ocular
anomaly.
1.3. Hypothesis
Seizures led to suspicion of a metabolic disorder, such as
hypoglycaemia. Encephalitis was also suspected; rabies was
considered. Epilepsy was excluded because of the associated
symptoms. Poisoning was excluded because of the duration
of symptoms. Fever and lymph node enlargement led to
increased suspicion of systemic infectious diseases like leish-
maniasis, ehrlichiosis, borreliosis, anaplasmosis or babesiosis.
Due to the travel history, infection by an indigenous African
infectious agent was considered. Lymphoma was not excluded.
1.4. Analysis
Routine biochemistry and haematology showed severe
hypoglycaemia (0.12 g/L, reference 0.6–1.1 g/L), normocytic
(mean corpuscular volume 72 fl; reference interval 61–77 fl),
normochromic (mean corpuscular haemoglobin concentration
33 g/dL; reference interval 33–36 g/dL), hyporegenerative
(reticulocytes 49,600/lL; reference interval 0–60,000/lL),
anaemia (haemoglobinaemia: 58 g/L, reference 120–180;
erythrocytes: 2.6 · 1012/L, reference 5.5–8.5 · 1012/L) and
thrombocytopenia (45 · 109/L, reference 200–500 · 109/L).
Blood type was DEA 1.1+. Other abnormalities included hyp-
oalbuminaemia (23 g/L; reference interval 25–35 g/L), hyper-
globulinaemia (59 g/L; reference interval 30–45 g/L) and
hypokalaemia (3.3 mmol/L; reference interval 3.8–5.2 mmol/L).
Lactate, blood gas, alkaline phosphatase, alanine aminotrans-
ferase, bilirubin, urea, creatinine, prothrombin time and
activated partial thromboplastin time were within reference
ranges. Urinalysis was unremarkable. Systolic, diastolic and
mean arterial blood pressures were within normal values.
A blood smear was prepared at the time of blood sample col-
lection and stained with Wright-Giemsa (Diff Quick). The
lymph nodes were aspirated and stained.
1.5. Diagnosis
Routine cytological examination of the blood smears
revealed numerous free extracytoplasmic protozoa (Fig. 2).
The parasites were 10–20 lm in length, 3 lm wide, with a
central nucleus, a medium-sized kinetoplast located at the body
margin, just in front of the posterior extremity (marginal and
sub-terminal kinetoplast), a poorly-developed undulating mem-
brane and no free flagellum (Fig. 3). This morphology is con-
sistent with Trypanosoma congolense [9]. The blood smears
showed no Babesia canis. Numerous trypanosomes were also
present in lymph node aspiration. These observations pointed
to a diagnosis of canine African trypanosomosis. Babesia
Figure 1. At presentation, the dog was cachectic, sleepy but
responsive, sternally or laterally recumbent.
Figure 2. Cytological examination of blood smears showed
numerous free parasites (May-Grünwald-Giemsa stain).
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and Leishmania serologies were negative at all dilutions.
Polymerase chain reaction (PCR) confirmed a Trypanosoma
congolense forest-type infection. All the other taxa-
specific PCRs were negative (Borrelia, Ehrlichia and
Leishmania).
1.6. Staff protection
Trypanosoma congolense does not infect humans and the
vector, the tsetse fly, is not present in France. No preventive
measures were taken for the medical staff, except, as for any
patient, not to handle biological fluids without gloves.
1.7. Critical care
The dog was transferred to the intensive care unit (ICU). On
admission to the ICU, two catheters were placed, one for fluid
administration and drug injection, the other for blood collection.
A naso-oesophageal tube was placed for sucrose administration.
1.7.1. Anaemia and thrombocytopenia management
Anaemia, thrombocytopenia, tachypnoea and tachycardia led
to transfusion of 10 mL/kg fresh whole blood. Mucous mem-
branes became more pink, heart rate and respiratory rates
returned to normal values and biological parameters improved
(haemoglobinaemia: 79 g/L; red blood cells: 3.6 · 1012/L;
thrombocytes: 135 · 109/L), but the dog remained in lateral or
sternal recumbency, unable to get up, sleepy, almost slumbering.
1.7.2. Hyperthermia management
On day 1, at 1 PM, the body temperature was 39.9 C;
at 2 PM 40.0 C; at 3 PM 39.8 C; and at 4 PM 39.6 C. Prac-
tical cooling methods were instituted: a fan, moist towel,
blocks of ice and alcohol wipes. They had no effect (Fig. 4).
1.7.3. Hypoglycaemia management
Hypoglycaemia was the major concern.
On day 1, at 1 PM, glycaemia was only 0.12 g/L and the
dog had a new seizure. The first measurements and most of
Figure 3. The protozoa are 10–20 lm in length and characterized
by a central nucleus, a medium-sized kinetoplast located at the
margin of the body, in a sub-terminal position (arrow), a poorly-
developed undulating membrane (arrowhead) and no free flagellum
(May-Grünwald-Giemsa stain).
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Figure 4. Temperature and glycaemia as a function of time.
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the very low measurements were carried out simultaneously
with a glucometer and a calibrated laboratory analyser
(Idexx); no discrepancy was found between them. The dog
was placed on a 5% glucose solution with 20 mmol/L KCl
at a rate of 1 mL/kg/h, except during transfusion. The severe
hypoglycaemia was treated with a 30 mL of 30% glucose IV
bolus injected slowly at the injection site of the maintenance
solution to prevent phlebitis. Ten millilitres of sucrose 70%
(7 g/10 mL), Canadou, a sugar syrup used for sweetening
cocktails, was administered by gavage tube.
At 4 PM, glycaemia was 0.63 g/L. At 5 PM, glycaemia was
0.2 g/L. From 6 PM until 3 PM on day 2, the dog had glyca-
emia measurements every hour, i.e. 26 measurements, all
below 0.25 g/L, with the exception of one of 0.36 g/L at
11 PM (Fig. 4). After each measurement, the dog received the
same supplements of glucose and water, i.e. 10 mL of sucrose
70% by gavage tube, 30 mL of glucose 30% IV through the
tubing of the CRI of 1 mL/kg of 5% glucose, and Hill’s a/d
food given by hand, for a total of about 20 g of glucose/hour
(1 g/kg/h) and 60 mL of fluids/hour (3 mL/kg/h). The dose
of glucose administered was approximately two times that usu-
ally recommended. Despite this support, no clinical or physio-
logical improvement was seen. Despite the lack of effect on
glycaemia, glucose supplementation was continued to prevent
the irreversible or even fatal neurological effects associated
with profound hypoglycaemia. At midnight, the dog presented
with head-shaking, the glycaemia then being 0.22 g/L.
At 4 PM, glycaemia was undetectable (‘‘value too low’’) with
the glucometer (the detection limit was 0.1 g/L).
At 6 PM on day 2, the dog received diazoxide,
Proglycem, at a dose of 2.5 mg/kg, a glucose-elevating drug
used to treat refractory hypoglycaemia induced by insulinoma.
Glycaemia increased. Glycaemia was 0.2 g/L at 5 PM, 0.32 g/L
at 6 PM, 0.53 g/L at 7 PM, 0.61 g/L at 8 PM, 0.57 g/L at 9 PM
and 1.08 g/L at 10 PM. At that time, the dog was standing
upright and was able to walk. Supplemental glucose was then
limited to a maintenance solution of 5% glucose at 1 mL/kg/h
supplemented with K+ and 10 mL of 70% sucrose by gavage
tube. The next four readings were nearly normal: 0.87 g/L at
11 PM, 1.18 g/L at 0:00 on day 3, 0.87 g/L at 2 AM, but by
4 AM glycaemia had dropped to 0.28 g/L. The initial treatment
every hour and diazoxide every 12 h were insufficient to
restore normoglycaemia, with values remaining around 0.4 g/L
all of the third day.
Every hour, after glycaemia and body temperature mea-
surements, the dog’s position was shifted in order to prevent
pressure ulcers. Arterial blood pressures, pulse and respiration
rates taken every hour were always within normal limits.
1.8. Specific treatment
Animal trypanocides are not available in metropolitan
France; as a result, a human product was used. The only drug
quickly available was pentamidine, Pentacarinate. It was
ordered, and arrived on day 3. Treatment consisted of six injec-
tions at 4 mg/kg at 48-hour intervals [1]. On day 3, at 2 PM,
the dog received an infusion of 80 mg pentamidine diluted
in 50 mL of 5% glucose (normal saline is contraindicated,
according to the manufacturer) over a period of 4 h in order
to watch for signs of anaphylaxis. No adverse effects were
noticed but hepatic parameters increased (ALP: 388, reference
0–200 IU/L, ALT: 201, reference 0–80 IU/L). The next five
doses were administered by intramuscular injection every
48 h. Glycaemia remained low and temperature high until
1 AM on day 4 before normalizing (Fig. 4). Clinical improve-
ment was correlated with the normalization of laboratory val-
ues. Trypanosomes had disappeared from the blood smears
four days following the first injection. On day 14, the day
following the last injection, the dog was discharged.
1.9. Relapses
Two weeks after discharge, or 1 month after initial presen-
tation, the dog again presented with the same symptoms, an
enlarged spleen and bilateral corneal opacity. Routine chemis-
try and haematology revealed anaemia (haemoglobinaemia:
66 g/L, erythrocytes: 2.8 · 1012/L), hypoglycaemia (0.68 g/L)
and thrombocytopenia (42 · 109/L). Many trypanosomes were
present on the blood smears. Ultrasound revealed marked
splenomegaly with multinodular parenchyma and a hypoechoic
pattern, consistent with reactive splenitis. A second transfusion
was performed. Thirteen glycaemia measurements during the
first 24 h were all low, with a minimum of 0.31 g/L and a max-
imum of 0.59 g/L (Fig. 4). Hypoglycaemia was treated as in
the first episode, with no greater success. The dog received
three other intramuscular injections of 4 mg/kg pentamidine
at 72-hour intervals.
Three weeks after the first relapse, or 7 weeks after the first
admission, the dog again presented, after a seizure. Haematol-
ogy still showed anaemia (erythrocytes: 4 · 1012/L) and
thrombocytopenia (120 · 109/L). Again, parasites were visible
on the blood smears. A third transfusion was performed.
Again, three intramuscular injections of 4 mg/kg pentamidine
were given, but at 10-day intervals. The dog came back for
monthly examinations for 3 months, upon which clinical examin-
ations, biochemistry and haematology were within normal ranges.
Three months, 6 months and 1 year after the last episode,
no trypanosomes were visible on the smears. The dog even
became pregnant 1 year later and gave birth to healthy puppies.
She was considered cured.
Six years after this incident the dog was presented for a
physical examination prior to another trip to Senegal; she
was healthy, no parasites were found on a blood smear, but
serological examination by ELISA T. congolense (using solu-
ble antigens of T. congolense Savannah-type) was positive.
PCR was negative.
2. Discussion
2.1. Canine trypanosomosis
There are six Trypanosoma species or types described in
carnivores worldwide [8]. T. cruzi, responsible for American
trypanosomosis or Chagas disease, is not present in Africa.
T. evansi is a trypanosome mainly found in camels in Senegal.
Dogs are rarely found to be infected with T. vivax, although
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there have been some reports in Cameroon [26]. The major
African trypanosomoses affecting dogs are T. congolense and
two subspecies of T. brucei: T. brucei brucei and T. b. gamb-
iense [11, 40]. In the present case, T. brucei and T. evansi were
ruled out based on morphologic criteria.
Three types of T. congolense are described (from the most
pathogenic to the least): T. congolense savannah-type is most
often found in cattle, in which it produces a rapidly fatal or severe
infection, whereas T. congolense forest-type causes more chronic
infection in cattle, but also in dogs. T. congolense kilifi-type is
rarely reported, since it usually causes an asymptomatic infection
[3]. These parasites are quite closely related and serological
responses show strong cross-reactions between the three para-
sites; thus both homologous and heterologous ELISAs can be
used to detect serological responses to these three parasites [6].
In the present case, a Nannomonas Trypanosoma sp. was
characterized by microscopic observation of the parasites; a
definitive diagnosis of T. congolense forest-type was reached
using PCR sequencing confirmation (Fig. 5) [8].
African animal trypanosomosis is called nagana in tropical
Africa. Trypanosomes are transmitted by tsetse flies of the
genus Glossina, widespread in this region [14]. The parasites
are ingested by the tsetse flies during a blood meal, where they
begin a development cycle, including multiplication in the vec-
tor; they may then be inoculated into another mammalian host.
Canine trypanosomosis caused by T. congolense is non-
zoonotic, but there is a human equivalent of nagana, human
African trypanosomosis, also known as sleeping sickness,
whose agents are Trypanosoma brucei gambiense and T. b.
rhodesiense, the vector of which is also the tsetse fly.
Canine African trypanosomosis is less common than
bovine trypanosomosis, a major constraint to livestock produc-
tivity; however, in endemic countries, the observed prevalence
in dogs can reach 30.1% [18]. In endemic countries, European
dogs die soon after trypanosomal infection, while African dogs
develop milder parasitaemias and may remain clinically
asymptomatic, possibly because of trypanotolerance [17].
Cases reported outside the endemic areas of Africa are all
imported.
To our knowledge, there are only five previous case reports
in Europe of canine African trypanosomosis in dogs other than
military.
The first case, published in a non-indexed journal, pre-
sented in France, was a German shepherd dog returning from
Senegal infected with Trypanosoma congolense [10]. He pre-
sented with lethargy, anorexia and hyperthermia. He recovered.
The second case, presented in Scotland, was a Jack Russell
Terrier returning from Mozambique infected with Trypanosoma
congolense savannah-type [13]. He presented with abdominal
distension, anaemia and thrombocytopenia, and died shortly
after admission. It must be emphasized that this animal spent
3.5 years in the UK before the infection was detected.
The third case, presented in the Netherlands, was a Vizla
returning from Senegal, that presented with anaemia; the
Trypanosoma species was not identified [33]. The dog was
treated with pentamidine and recovered.
The fourth case was in France, a German wire-haired poin-
ter returning from Senegal infected with Trypanosoma congo-
lense savannah-type [23]. He presented with anaemia and
thrombocytopenia, and died 2 weeks later.
The fifth case was also in France, in a Shih Tzu returning
from Senegal infected with atypical hyperpachymorph Trypan-
osoma congolense forest-type [9]. He presented with anaemia
and died four days after admission.
Besides these dogs owned by individuals, canine trypanos-
omosis is regularly observed in France in military working
dogs returning from sub-Saharan African countries [5, 18, 37].
2.2. Hypoglycaemia
Hypoglycaemia is the most notable clinical feature of this
case. Hypoglycaemia is part of the classical presentation of
Figure 5. Comparison of the dog’s trypanosome sequence with the
reference sequence published by Masiga et al. [21].
Figure 6. 1: Molecular marker (PhiX174/HaeIII); 2, 3, 6, 7, 10, 11,
14, 15: blood of the dog; 4: T. congolense savannah-type positive
control; 8: T. congolense forest-type positive control; 12: T. vivax
positive control; 16: T. brucei positive control; 5, 9, 13, 17: negative
controls.
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trypanosomosis; it has been reported in several species, as in
buffaloes [19], in buffalo calves [20], in goats [24], in camels
[27], in a tiger [34], in a dog [15] and in a human [25].
Hypoglycaemia explains the lethargy and convulsions. The
fact that the dog was able to stand and walk when her blood
sugar rose to 1.08 g/L (at 10 PM on day 2) reinforces the
impression that symptoms were due mainly to hypoglycaemia.
Hypoglycaemia was spectacular in its severity: most values
were <0.4 g/L and often close to 0.2 g/L, which in general is
not compatible with life. However, the clinical effects were less
severe than the laboratory values would suggest. At 4 PM on
day 1, blood glucose was undetectable, yet the dog was not
comatose or convulsing.
The most striking observation was its refractory nature.
There was a total lack of response to glucose administration.
Severe hyperglycaemias are sometimes reported, but intrave-
nous or oral glucose administration always causes an increase
in glycaemia, at least temporary. Every hour, this dog received
7 g of oral sucrose, 10 g of IV glucose and rich food, for a total
of almost 20 g of sugar every hour (1 g/kg/h), or 500 g of pure
sugar per day. In total, over the four days that hypoglycaemia
lasted, the dog received 2 kg of pure sugar (equivalent to
two boxes of sugar), without any effect. The same phenomenon
happened again during the first relapse, when the dog received
almost 1 kg of pure sugar in two days. To our knowledge, such
severe hypoglycaemia in the context of such aggressive glu-
cose supplementation has never been reported in the veterinary
literature.
The origin of this severe and refractory hypoglycaemia was
a crucial diagnostic question. Sepsis-induced hypoglycaemia is
usually less pronounced, and not refractory. The hypothesis of
rebound hypoglycaemia was rejected, because we never
observed hyperglycaemic peaks. We did not measure insulin
levels. Severe hypoglycaemia and hyperinsulinaemia have been
observed in human patients infected with Plasmodium falcipa-
rum, attributed in part to large glucose requirements of malaria
parasites [38]. In our patient, as soon as trypanosomes disap-
peared from the blood smears, glycaemia and temperature nor-
malized. Trypanosomes appeared to be directly responsible for
hypoglycaemia and hyperthermia. It was as if glucose adminis-
tered to the dog only served to feed the trypanosomes, indicat-
ing that treatment of hypoglycaemia may have been detrimental.
We found old studies in the 1930s that seem to support this
hypothesis. Trypanosomes use enormous amounts of sugar for
their metabolism; they consume twice their own mass of sugar
within 24 h [39]. Insulin injection into dogs or rats infected
experimentally leads to a reduction in the number of trypano-
somes [29, 30]. In infected rats, hyperglycaemia after injection
of glucose increased the population of trypanosomes [4, 28].
Trypanosome mobility decreased in blood samples at room
temperature, but moribund trypanosomes could be revived by
the addition of sugar [31]. In 1937, hypoglycaemic therapy
was considered for the management of trypanosomosis
[2, 31, 36], but this line of study was abandoned with the arri-
val of trypanocides [32].
These old experimental studies were reinforced by two
clinical observations in human patients.
In a case reported in the United States to CDC internal
records, a diabetic patient with African trypanosomosis
required less insulin during the acute phase of his illness
(Ackley A., personal communication, quoted by Nieman
[12, 25]).
Another case observed in the United States described
severe African trypanosomosis with spurious hypoglycaemia
in a 58-year-old woman returning from Kenya and Rwanda
[25]. Despite severe hypoglycaemia on admission (0.21 mg/L),
the patient was fully alert, with no clinical manifestation of
hypoglycaemia. Despite the IV injection of hypertonic glucose
solutions, blood glucose levels continued to register as
<0.50 mg/L. The authors considered the possibility of spurious
hypoglycaemia due to in vitro utilization of glucose by trypan-
osomes. They drew two blood samples simultaneously. The
first sample was placed on ice and carried to the laboratory;
the glucose level was 1.03 mg/L. In the second sample, not
placed on ice and analysed at the same time, the glucose level
was only 0.48 mg/L. At the same time of venepuncture, in a
capillary blood specimen, the blood glucose level, given by a
rapid assay method (Accucheck), was 1.07 mg/L. In our case,
most measurements were performed with a glucometer,
immediately after the sample was drawn, or with an analyser
located in the ICU, so the possibility of spurious hypoglycae-
mia is improbable. However, this case emphasizes the large
consumption of glucose by trypanosomes, even ex vivo.
2.3. Specific treatment and follow-up
There are no trypanocides currently available in metropol-
itan France although some of them may be found. Melarso-
mine dihydrochloride, sold for the control of heart worm
under the registered name Immiticide, is a trypanocide also
sold in Africa under the registered name Cymelarsan for the
control of surra (sub-genus Trypanozoon) in camels; it is not
known as an active trypanocide against the sub-genus Nano-
monnas, so it would not be suitable for the present case.
Nifurtimox, a human drug, may be found in hospitals but
rather targets Trypanosoma cruzi, and was not fully validated
against Trypanozoon parasites; moreover, it may not be well
suited for animal treatments. Pentamidine was discovered
accidentally in 1937 in the course of research on blood sugar
lowering agents which have the ability to disrupt the parasite’s
energy metabolism [32]. Pentamidine is used in humans for the
control of T. brucei ssp. (Trypanozoon). It was not evaluated
against T. congolense in animals, and as a result, there are
no data available on its efficacy against T. congolense or on
resistance. Diminazene aceturate is not available in France
and is thought to be toxic in dogs. However, it is currently used
in dogs in Africa and Asia respectively against T. congolense
and T. evansi [7]. Pentamidine was shown to be more efficient
than diminazene (Berenil), the standard veterinary trypano-
cide, in the treatment of T. brucei brucei infection in dogs
[1]. Isometamidium (Trypamidium) requires only a single
intramuscular injection at 1 mg/kg, but is only available in
Africa. Isometamidium is used every 2 months for chemopro-
phylaxis in military dogs in sub-Saharan Africa [37].
This is the third non-fatal case of canine African trypanos-
omosis reported [10, 33].
Two relapses were observed. Failures in trypanocide treat-
ments originate from (i) an extravascular refuge of the parasite
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(which generally induces late or very late relapses), (ii) insuf-
ficient treatment (underdosage, incorrect route of administra-
tion, contamination, counterfeit product, etc.) or (iii) parasite
chemoresistance. In the last two cases, the relapse generally
occurs within 2–4 weeks, due to the fact that some of the par-
asites have not been killed. In our study, the treatment proce-
dure was carefully applied and is considered to be reliable in
terms of trypanocide quality, quantity and administration
route. In this case, after a first series of six pentamidine
administrations, the very early relapse observed is suggestive
of parasite chemoresistance to pentamidine. Indeed, the sec-
ond series of treatments was also followed by a very early
relapse, which confirms the fact that some of the circulating
parasites were not killed by the trypanocide treatment. More
problematic is the fact that the parasite disappeared after the
third treatment at the same dose, but applied at 10-day inter-
vals. It is hypothesized that repeated treatments, that proved
to be sub-curative, may have enhanced the immune system
and have finally led to either a self-cure or a clinical cure with
sustainable control of the parasitaemia down to undetectable
levels. Iterative treatments that proved to be sub-curative
would then be a way to achieve a curative treatment protocol.
However, such situations reveal pre-existing drug resistance
and would even increase the selection of more resistant strains
which would be another important concern in enzootic
countries.
The actual status of the dog in our case is questionable.
There are no specific data available on the persistence of anti-
bodies to trypanosomes in dogs. However, based on the obser-
vations made in livestock [35], persistence of antibodies
6 years after a cure is not expected. Seropositivity 6 years
after this episode is rather suggestive of healthy carrying of
the parasite. This hypothesis could not be confirmed by
PCR based on a blood sample collected in November 2015,
since it was negative. At this stage, laboratory results suggest
that the dog is still infected, but remain unable to confirm
infection. Due to this uncertain status, it is highly recom-
mended to administer a new treatment to the dog, in order
to eliminate potential carrying. Quinapyramine salts (sulfate
and chloride) at 5 mg/kg is suggested. Later on, the animal
should be followed up using ELISA T. congolense (and
PCR). A successful curative treatment would most probably
lead to negative seroconversion within 6 months post-treat-
ment, as is usually observed with African trypanosomosis
in other animals.
In the present case, the risk of transmission to humans
was low, since (i) T. congolense does not affect humans;
and (ii) the parasite requires a vector not present in France.
However, dogs can be infected with T. brucei that infect
humans and mechanical infection can occur in areas where
tsetse flies are not present. Quarantine after return from ende-
mic countries is sometimes recommended [16]. Quarantine
could however be insufficient because the incubation period
can be very long. In the case reported by Gow et al., the
asymptomatic period was 3.5 years [13]. Our dog might also
be an asymptomatic carrier 6 years after her apparent cure.
Dogs that return from endemic countries of human trypanoso-
miasis should be investigated by molecular screening as well
as serological tools.
2.4. PCR strain identification
The virulence of Trypanosoma congolense varies greatly
with type. Therefore, PCR analysis of whole blood was per-
formed to correctly identify this Trypanosoma sp. and type.
The sensitivity of PCR is two to three times higher than micro-
scopic observation of the buffy coat, and the sensitivity thresh-
old of trypanosome detection generally ranges from 1 to 20
parasites/mL of blood. For monospecific PCR identification,
the most favoured target is minichromosomal nuclear satellite
DNA, which has the advantage of a highly repetitive short
sequence (10,000–20,000 repeats; 120–600 bp). Specific satel-
lite primers were used for Trypanozoon, T. vivax, T. congolense
savannah-type, T. congolense forest-type [21, 22]. The result-
ing PCR amplification product of 350 bp, expected with
T. congolense forest-type infection using TCF1/TCF2 primers,
can be visualized on an agarose gel after staining with ethidium
bromide and exposure under ultraviolet light (Fig. 6). The
specific size of the PCR product was evaluated by
simultaneous migration of molecular size markers and of a
positive control [8]. The sequence of the amplification product
shows 97% identity with the published reference sequence of
Masiga et al. [21] (Fig. 5). Additionally, Pan-trypanosome pri-
mer sets were used for Trypanosoma spp. detection: TRYP4
and nested PCR targeting the 18S-ITS1 region, confirming
the presence of T. congolense forest-type (data not shown).
3. Conclusion
In this dog, infection with Trypanosoma congolense
forest-type caused severe hypoglycaemia refractory to sugar
supplementation. It is possible that the drastic treatment of
hypoglycaemia had the paradoxical effect of promoting try-
panosome survival. The dog survived but is suspected of being
an asymptomatic carrier 6 years after her apparent cure.
Further treatment and follow-up should help to clarify and
hopefully solve this unclear status.
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